Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
The authors reported a cryo-MicroED structure of cefadroxil, characterizing its molecular geometry, stereochemistry, and intermolecular packing. The crystallographic model also supported complementary molecular-dynamics analysis. This is a structural case study of an established beta-lactam antibiotic; the accompanying computational work should not be interpreted as clinical evidence of a new neurotherapeutic benefit or a general performance guarantee.
Hansoh presented two randomized, double-blind, placebo-controlled Phase 1 studies of HS-20118 involving 129 treated participants, including healthy volunteers and 23 patients with psoriasis. The company reported sustained pharmacokinetic and pharmacodynamic activity and early skin-response signals supporting exploration of weekly oral dosing. Small patient cohorts and short treatment duration limit conclusions about comparative efficacy and long-term safety.
BioAgilytix reviewed its earlier analytical investment in Morrisville and Hamburg, describing infrastructure for GMP QC, characterization, bioassays, release, and stability programs. This is a May 2026 company update about previously expanded capabilities, not a newly announced November facility opening or independent quality certification.
Merck announced a Science publication describing large-scale biocatalytic synthesis of enlicitide. Engineered enzymes enable peptide-fragment formation, coupling, and macrocyclization, combined with crystallization-based purification. The work addresses manufacturing of a complex orally available macrocyclic peptide. It provides a process-development example rather than new clinical efficacy evidence or a universally transferable route for every macrocycle.
Haisco disclosed clinical-trial clearance for HSK47388(I) tablets in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, while its psoriasis program was already in Phase 2. The filing describes preclinical effects in rat colitis models, not patient efficacy. This milestone expands authorized clinical development and is not marketing approval or confirmation of therapeutic benefit.
An automated molecular-replacement workflow solved the electron-diffraction structure of corilagin, a macrocyclic gallotannin that resisted ab initio phasing. Validation used known paritaprevir and grazoprevir structures across several resolution cutoffs. The results suggest an alternative route for flexible or lower-quality small-molecule datasets, with the important condition that chemically appropriate trial conformations must be available.
Sunshine Guojian discussed its 629 oral IL-23 cyclic peptide program in an investor-relations record, saying pharmacokinetic findings suggest potential for weekly dosing. The document did not provide study species, participant details, quantitative exposure, or clinical outcomes. These are company development claims and do not establish validated human bioavailability, weekly clinical efficacy, or an approved dosing regimen.
Syneron Bio announced a $150 million Series B financing that closed on March 31. An international life-science fund led the round, with Decheng Capital, CDH VGC, and other investors participating. Proceeds will develop Synova and advance oncology, autoimmune, metabolic, and rare-disease programs toward the clinic. Named candidates, enrollment milestones, and human oral pharmacokinetics were not disclosed.
Triastek announced FDA IND clearance for T25, a modified-release oral octreotide acetate tablet intended for maintenance treatment of adults with acromegaly who respond to somatostatin analogs. The candidate combines MED&SSE printing with its 3D microstructure delivery system. Clearance enables clinical development; the announcement did not provide human pharmacokinetic or efficacy results.
Pinnacle Medicines closed an $89 million Series B co-led by LAV and Foresite Capital, bringing disclosed funding to $134 million. Proceeds support oral peptide programs toward clinical proof of concept, initially in immunology and cardiometabolic disease, alongside expansion of AI and physics-based discovery capabilities. The announcement does not provide new human efficacy results.
FDA approved icotrokinra, marketed as ICOTYDE, on March 17; Johnson & Johnson announced the decision the following day. The once-daily oral IL-23 receptor antagonist is indicated for eligible adults and patients aged 12 or older weighing at least 40 kg with moderate-to-severe plaque psoriasis. The approval does not extend to ulcerative colitis or other investigational indications.
Unnatural Products closed a $45 million Series B led by The Venture Collective, with argenx, Droia, and existing investors participating. Funding supports its computational design, automated chemistry, high-throughput screening platform, and macrocyclic peptide pipeline. The oral-delivery strategy remains a development objective; this financing announcement does not establish human oral efficacy for a newly disclosed candidate.
